Cannabinoid-induced changes in respiration of brain mitochondria |
| |
Authors: | Zdeněk Fi&scaron ar,Namrata Singh,Jana Hroudová |
| |
Affiliation: | Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, Prague 2 120 00, Czech Republic |
| |
Abstract: | Cannabinoids exert various biological effects that are either receptor-mediated or independent of receptor signaling. Mitochondrial effects of cannabinoids were interpreted either as non-receptor-mediated alteration of mitochondrial membranes, or as indirect consequences of activation of plasma membrane type 1 cannabinoid receptors (CB1). Recently, CB1 receptors were confirmed to be localized to the membranes of neuronal mitochondria, where their activation directly regulates respiration and energy production. Here, we performed in-depth analysis of cannabinoid-induced changes of mitochondrial respiration using both an antagonist/inverse agonist of CB1 receptors, AM251 and the cannabinoid receptor agonists, Δ9-tetrahydrocannabinol (THC), cannabidiol, anandamide, and WIN 55,212-2. Relationships were determined between cannabinoid concentration and respiratory rate driven by substrates of complex I, II or IV in pig brain mitochondria. Either full or partial inhibition of respiratory rate was found for the tested drugs, with an IC50 in the micromolar range, which verified the significant role of non-receptor-mediated mechanism in inhibiting mitochondrial respiration. Effect of stepwise application of THC and AM251 evidenced protective role of AM251 and corroborated the participation of CB1 receptor activation in the inhibition of mitochondrial respiration. We proposed a model, which includes both receptor- and non-receptor-mediated mechanisms of cannabinoid action on mitochondrial respiration. This model explains both the inhibitory effect of cannabinoids and the protective effect of the CB1 receptor inverse agonist. |
| |
Keywords: | ADP, adenosine diphosphate AM251, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide cAMP, cyclic adenosine monophosphate CB, cannabinoid receptor DMSO, dimethyl sulfoxide FCCP, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone IC50, drug concentration that is required for 50% inhibition Ki, affinity for receptor MiR05, mitochondrial respiration medium OXPHOS, oxidative phosphorylation PKA, protein kinase A THC, Δ9-tetrahydrocannabinol TMPD, tetramethyl-p-phenylenediamine WIN 55,212-2, R-(+)-WIN 55,212, R-(+)-[2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone |
本文献已被 ScienceDirect 等数据库收录! |
|